Courtney Thorne

Partner
Full contact info

I take life sciences companies public and then I'm there to help clients navigate the waters of being an SEC reporting company.

Passions

Exploring neighborhood coffee shops

Volunteering with the Junior League of Boston

Travel

Experience

CinCor Pharma – $212 Million IPO

January 7, 2022

Cooley advised CinCor Pharma on its upsized $212 million initial public offering of 13,290,813 shares of common stock, which included a partial exercise of the underwriter’s option to purchase additional shares of common stock. CinCor, whose shares now trade on the Nasdaq Global Market under the symbol CINC, is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor’s IPO was one of the first IPOs of 2022. Partners Ryan Sansom, Div Gupta and Courtney Thorne led the Cooley team.

Related contacts

Ryan Sansom
Partner, Boston
Div Gupta
Partner, New York
Courtney Thorne
Partner, Boston
Barry Kuang
Associate, Boston
Alexander Fullman
Associate, New York
Kyle Birnbaum
Associate, New York
Cathy Rude
Senior Paralegal, Boston
Danielle Gershowitz
Associate, New York

Exscientia – $510.4 Million IPO

October 6, 2021

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Read more

Related contacts

David Boles
Partner, London
Claire Keast-Butler
Partner, London
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
David Wilson
Partner, London
Chris Stack
Partner, London
Dayne Brown
Associate, New York
Margaret D. Suh
Associate, New York
Charles George
Associate, London
Meg Begur
Associate, London
Nicola Squire
Partner, London
Jack Jones
Associate, London
Charlotte Irvine
Associate, London
Tom Goodman
Partner, London
Paula Holland
Partner, London
Aaron Pomeroy
Partner, Colorado
Calvin Lee
Associate, New York
Ivor Elrifi
Partner, New York
Courtney Thorne
Partner, Boston

Finch Therapeutics – $128 Million IPO

April 8, 2021

Cooley advised Finch Therapeutics on its $127.5 million initial public offering of 7,500,000 shares of common stock. Finch Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol FNCH, is a clinical-stage microbiome therapeutics company. Partners Div Gupta and Ryan Sansom led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Ryan Sansom
Partner, Boston
Courtney Thorne
Partner, Boston
Trey Reilly
Associate, New York
Michael Bruno
Associate, New York
Pengli Li
Associate, Boston

Immunocore – $297 Million IPO

February 5, 2021

Cooley advised Immunocore on its $297.1 million initial public offering of 11,426,280 American depositary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Immunocore, whose securities now trade on the Nasdaq Global Market under the symbol IMCR, is a late-stage biotechnology company pioneering the development of a novel class of T-cell receptor bispecific immunotherapies designed to treat a broad range of diseases. Partners Div Gupta, Eric Blanchard, Nicola Maguire and Claire Keast-Butler led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Eric Blanchard
Partner, New York
Nicola Maguire
Partner, London
Claire Keast-Butler
Partner, London
Courtney Thorne
Partner, Boston
Tom Goodman
Partner, London
Mark Jones
Associate, London
Sam Meiklejohn
Associate, London
Harry Calkin
Associate, London
Charles George
Associate, London
Dominic Taylor
Associate, London

Nanobiotix – $113 Million IPO

December 10, 2020

Cooley advised the underwriters on Nanobiotix’s $113.3 million initial public offering of 8,395,000 ordinary shares (global offering) – including the offering of 6,540,000 American depositary shares, each representing one ordinary share, in the US (the US offering) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the US to certain investors (the European offering) – which includes the full exercise of the underwriters’ option to purchase additional shares. Jefferies acted as global coordinator and joint book-running manager for the global offering; Evercore Group and UBS Securities acted as joint book-running managers for the US offering; and Gilbert Dupont acted as manager for the European offering. Nanobiotix, whose securities now trade on the Nasdaq Global Select Market under the symbol NBTX, also trades on the Euronext Paris Market under the symbol NANO. Nanobiotix is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancers. Partners Brian Leaf, Div Gupta and David Boles led the Cooley team.

 

Related contacts

Div Gupta
Partner, New York
David Boles
Partner, London
Courtney Thorne
Partner, Boston
Katie Kazem
Partner, Reston
William DuVal
Associate, Reston
Rasha Printz
Associate, Reston
View more

Rankings & accolades

Massachusetts Super Lawyers: Rising Star in Business/Corporate Law and Securities & Corporate Finance
(2015 – 2022)

#1 Firm for European FPI US IPOs since 2016

Memberships & affiliations

Boston Bar Association

Healthcare Businesswomen's Association

PubCo @ Cooley Blog

Focus on providing dynamic thought leadership and curated content for the public securities arena